Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy?
Eli Lilly LLY and AstraZeneca AZN are leading drugmakers with significant involvement in oncology, immunology, and the cardiometabolic disease space. Both are making substantial investments in next-generation therapies such as cancer immunotherapies, treatments for respiratory conditions as well as GLP-1 drugs. With robust, research-driven pipelines and strong growth potential, they represent an intriguing comparison for investors considering large-cap pharmaceutical stocks.
Though both companies have a diversified product profile, Lilly's largest segment is Cardiometabolic Health, which accounts for 72% of its total revenues. Lilly has a strong portfolio of medicines to treat diabetes and other cardiometabolic diseases. Its cardiometabolic business is its most successful business, particularly with the success of its popular GLP-1 drugs, Mounjaro for diabetes and Zepbound for obesity.
On the other hand, Oncology is AstraZeneca's biggest segment, comprising around 41% of its total revenues. The company is working on strengthening its oncology product portfolio through label expansions of existing products and advancement of oncology pipeline candidates.
Both Lilly and AstraZeneca are seeing strong sales and earnings growth. But which one is a better investment today? Let's take a closer look at their fundamentals, growth prospects and challenges to make an informed choice.
Lilly boasts a wide range of products that serve a vast number of therapeutic areas. The company focuses primarily on cardiometabolic health, neuroscience, oncology and immunology, which are all high-growth areas with significant commercial potential.
Despite being on the market for less than three years, Mounjaro and Zepbound became key top-line drivers for Lilly, with demand rising rapidly. Mounjaro and Zepbound generated combined sales of $6.15 billion in the first quarter of 2025, accounting for around 48% of the company's total revenues.
Though sales of Mounjaro and Zepbound were below expectations in the second half of 2024, hurt by slower-than-expected growth and unfavorable channel dynamics, their sales picked up in the first quarter of 2025, driven by launches of the drugs in new international markets and improved supply from ramped-up production. We believe that increased uptake in outside U.S. markets and deeper penetration in the U.S. market will continue to drive Mounjaro and Zepbound's growth in future quarters. Approvals for new indications can also drive sales of Mounjaro and Zepbound higher.
Other than Mounjaro and Zepbound, Lilly has gained approvals for some other new drugs in the past couple of years across different therapeutic areas like Omvoh, Jaypirca, Ebglyss and Kisunla (donanemab). Lilly expects its new drugs, Mounjaro, Zepbound, Omvoh, Jaypirca, Ebglyss and Kisunla, along with the expanded use of existing drugs, to drive sales growth in 2025.
Lilly is also making rapid pipeline progress in obesity, diabetes and cancer, with several key mid and late-stage data-readouts expected this year. Lilly is investing broadly in obesity and has several new molecules currently in clinical development.
In terms of capital allocation, LLY returned $2.5 billion to shareholders in the first quarter via share repurchases and dividends. The board of directors of Lilly approved a new $15 billion stock buyback plan and also announced a 15% increase in its quarterly dividend in 2024.
Lilly has its share of problems. Sales of its key medicine, Trulicity, are declining in the United States due to competitive dynamics, including Mounjaro switches and supply constraints. Prices of most of Lilly's products are declining in the United States. Potential competition in the GLP-1 diabetes/obesity market is another headwind.
The stock also took a hit this month because CVS Caremark, a major pharmacy benefit manager ('PBM'), announced a partnership with rival Novo Nordisk NVO to make NVO's Wegovy its preferred GLP-1 therapy for weight loss, effective July 1.
NVO also recently announced partnerships with telehealth providers Hims & Hers Health to offer Wegovy at a discounted price to cash-paying patients. Though Lilly's CEO, Dave Ricks does not expect CVS' decision to exclude Zepbound in favor of Wegovy to hurt Lilly's revenues, we believe it may hurt Zepbound's market share.
Headquartered in Cambridge, the United Kingdom, AstraZeneca boasts a diversified geographical footprint as well as a product portfolio with several blockbuster medicines. AstraZeneca now has 16 blockbuster medicines in its portfolio with sales exceeding $1 billion, including Tagrisso, Fasenra, Farxiga, Imfinzi, Lynparza, Calquence and Ultomiris. These drugs are driving the company's top line, backed by increasing demand trends. The company is confident that the growth will continue in 2025. Almost every new product it has launched in recent years has done well.
Newer drugs like Wainua, Airsupra, Saphnelo, Datroway (partnered with Daiichi Sankyo) and Truqap are also expected to continue to contribute to top-line growth in 2025.
Backed by its new products and pipeline drugs, AstraZeneca believes it can post industry-leading top-line growth in the 2025-2030 period. AstraZeneca expects to generate $80 billion in total revenues by 2030, a significant increase from the $54 billion it generated in 2024. By the said time frame, AstraZeneca plans to launch 20 new medicines, with nine new medicines already launched/approved. It believes that many of these new medicines will have the potential to generate more than $5 billion in peak-year revenues.
The company is also on track to achieve a mid-30s percentage core operating margin by 2026.
AstraZeneca faces its share of challenges. The impact of Part D redesign hurt sales of AZN's older drugs, Tagrisso, Lynparza and Ultomiris, as well as newer drugs, Truqap and Wainua, in the United States in the first quarter of 2025, with the trend expected to continue through the rest of the year. AstraZeneca expects Farxiga and Lynparza to be included in the volume-based procurement plans in China in mid-2025, which can hurt sales of these drugs in the country.
Pricing and competitive pressure in Europe and generic competition in some emerging markets are expected to hurt drug sales. In 2025, generic/biosimilar competition in the United States is expected to hurt sales of key drugs like Brilinta and Soliris. Sales in its Rare Disease segment are expected to be slower in 2025 than in 2024.
As regards shareholders' returns, AstraZeneca intends to increase its annual dividend per share to $3.20 per share in 2025.
The Zacks Consensus Estimate for LLY's 2025 sales and EPS implies a year-over-year increase of 32.6% and 70.0%, respectively. EPS estimates for 2025 as well as 2026 have declined over the past 60 days.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for AstraZeneca's 2025 sales and EPS implies a year-over-year increase of 6.7% and 9.3%, respectively. EPS estimates for both 2025 and 2026 have risen over the past 60 days.
Image Source: Zacks Investment Research
Year to date, while LLY's stock has declined 5.7%, AstraZeneca's stock has risen 9.8%. The industry has declined 4.5% in the said time frame.
Image Source: Zacks Investment Research
Both Lilly and AZN are priced higher than the industry from a valuation standpoint. Lilly is more expensive than AstraZeneca, going by the price/earnings ratio. Lilly's shares currently trade at 28.31 forward earnings, higher than 15.13 for AZN. However, both AZN and LLY are trading at discounts to their 5-year mean.
Image Source: Zacks Investment Research
Lilly's dividend yield is 0.8%, while AZN's is much higher at around 2.9%.
Image Source: Zacks Investment Research
Lilly's return on equity of 85.5% is higher than AZN's 33.1%.
Both Lilly and AstraZeneca have a Zacks Rank #3 (Hold), which makes choosing one stock a difficult task. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Lilly is a good stock to have in one's portfolio, considering its diversified product and pipeline portfolio and robust growth prospects despite its expensive valuation. Lilly's tremendous success with Mounjaro and Zepbound has made it the largest drugmaker with a market cap of more than $650 billion. In 2025, Lilly expects to record revenues in the range of $58.0 billion to $61.0 billion, indicating an impressive 32% year-over-year growth.
However, considering Lilly's several near-term challenges, AstraZeneca looks like a safer bet for short-term investors, given its price appreciation, cheaper valuation and robust growth prospects. Despite the potential impact from Part D redesign, AstraZeneca expects total revenues to grow by a high single-digit percentage at CER in 2025. AstraZeneca expects core EPS to increase by a low double-digit percentage. Consistently rising estimates also indicate analysts' optimistic outlook for growth.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AstraZeneca PLC (AZN) : Free Stock Analysis Report
Novo Nordisk A/S (NVO) : Free Stock Analysis Report
Eli Lilly and Company (LLY) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
4 hours ago
- Medscape
Merck's Potential Blockbuster Cholesterol Pill Succeeds in Late-stage Studies
(Reuters) -Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond its cancer drugs and vaccines. The company is searching for its next blockbuster candidate as its major revenue driver, Keytruda, is expected to lose patent protection by the end of the decade. Merck's non-statin cholesterol drug, enlicitide decanoate, is being tested for the treatment of hyperlipidemia, a condition that causes elevated buildup of fat in the blood vessels and can lead to heart attacks and strokes. Enlicitide works by blocking PCSK9, a protein that plays a crucial role in regulating cholesterol levels, while statins block an enzyme the liver uses to make cholesterol. BMO Capital Markets analyst Evan Seigerman said Merck's drug could potentially provide a "multi-billion dollar opportunity" that expands the PCSK9 market beyond current injectable therapies. The drug showed meaningful reductions in LDL-C cholesterol, commonly referred to as "bad cholesterol", when compared to placebo and other oral non-statin therapies, Merck said. However, Leerink analysts have noted that Astrazeneca's AZD0780 is a "credible threat" as it has shown a 50.7% reduction in LDL-C levels during a trial. Merck has not given the details on LDL-C reduction for enlicitide. The drug was tested in patients who have a history of, or are at risk for a type of heart disease, and were treated with a statin. Shares of Merck were up 2% in premarket trading. Verve Therapeutics is also developing a gene therapy to reduce high cholesterol levels, which is expected to be used in combination with other drugs. (Reporting by Christy Santhosh in Bengaluru; Editing by Shinjini Ganguli)
Yahoo
4 hours ago
- Yahoo
Eli Lilly and Company (LLY): A Bull Case Theory
We came across a bullish thesis on Eli Lilly and Company (LLY) on Business Model Mastery's Substack. In this article, we will summarize the bulls' thesis on LLY. Eli Lilly and Company (LLY)'s share was trading at $765.68 as of 5th June. LLY's trailing and forward P/E were 62.30 and 35.09 respectively according to Yahoo Finance. A picture of a pharma technician preparing an IV injection of a biopharmaceutical product. Eli Lilly is no longer just a pharmaceutical giant—it's becoming a platform company that's reshaping the very structure of global healthcare. At the heart of this transformation is tirzepatide, a dual-action molecule marketed under separate brands for diabetes and obesity. This single drug now accounts for over a quarter of Lilly's total revenue, with the diabetes version generating $11.5 billion (up 330% YoY) and the obesity variant reaching $2.3 billion in its first year—a historic ramp-up. These are not just growth numbers; they're margin-rich results, with 85 %+ gross margins and minimal marketing spend due to entrenched trust among endocrinologists. Crucially, tirzepatide is protected by a fortress of patents through 2036 and beyond, giving Lilly a durable edge in two massive markets. Unlike peers, Lilly owns its injectable manufacturing end-to-end, having invested over $5.5 billion in internal capacity, giving it unmatched agility and control while rivals struggle with supply constraints. Its sales force and deep prescriber relationships, built over decades, have only grown more powerful thanks to a new direct-to-consumer platform that streamlines initiation and adherence. Meanwhile, the company is reinvesting aggressively, with $11 billion (24% of revenue) spent on focused R&D spanning Alzheimer's, oncology, and rare diseases. Its pipeline—anchored in metabolic, neurodegenerative, and immune disorders—builds on existing strengths, accelerating commercialization. Competition exists, but Lilly's molecule consistently outperforms, and its infrastructure outscales. With two-thirds of sales still U.S.-based, global expansion represents the next lever. In sum, Lilly's model—a convergence of science, scale, and system—positions it as more than a pharma company. It's a precision biology platform with extraordinary strategic depth and long-term compounding potential. Previously, we covered a bullish thesis on Eli Lilly (LLY) by Kontra on Substack in May 2025, which aligns with Business Model Mastery's analysis, emphasizing the company's leadership in obesity and diabetes care. Both highlight tirzepatide's explosive growth, margin strength, and Lilly's massive investment in capacity and R&D. Kontra focuses more on near-term financial results, pipeline expansion, and regulatory catalysts, while Business Model Mastery frames Lilly as a precision biology platform with structural advantages—like end-to-end manufacturing and patent longevity—that support durable outperformance. Together, they reinforce Lilly's status as a long-term compounder with deep moats and global runway. Eli Lilly and Company (LLY) is on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 119 hedge fund portfolios held LLY at the end of the first quarter which was 115 in the previous quarter. While we acknowledge the risk and potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Associated Press
9 hours ago
- Associated Press
IonQ Speeds Quantum-Accelerated Drug Development Application With AstraZeneca, AWS, and NVIDIA
COLLEGE PARK, Md.--(BUSINESS WIRE)--Jun 9, 2025-- IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, announced results of a collaborative research program between IonQ, AstraZeneca, Amazon Web Services (AWS), and NVIDIA to develop and demonstrate a quantum-accelerated computational chemistry workflow which has the potential to power world-changing innovation in healthcare, life sciences, chemistry, and more. The results of the collaboration will be showcased at the ISC High Performance conference, which takes place on June 10-13, 2025, in Hamburg, Germany. The IonQ-designed workflow provides an end-to-end example of a hybrid quantum-classical workflow that helps provide solutions to complex pharmaceutical development challenges, and has the potential to improve speed and efficiency within the drug development process. Developing new drugs can take ten or more years and cost billions of dollars, so advancements that streamline early-stage research and reduce computational bottlenecks can unlock significant strategic and commercial value. This demonstration focused on a critical step in a Suzuki-Miyaura reaction – a class of chemical transformations used for the synthesis of small molecule drugs. By integrating IonQ's Forte quantum processing unit (QPU) with the NVIDIA CUDA-Q platform through Amazon Braket and AWS ParallelCluster services, the team achieved more than 20 times improvement in end-to-end time-to-solution compared to previous implementations. The technique maintained accuracy while reducing the overall expected runtime from months to days. 'This demonstration with AstraZeneca represents a meaningful step toward practical quantum computing applications in chemistry and materials science and showcases how IonQ's enterprise-grade quantum computers are uniquely suited to meet the challenge,' said Niccolo de Masi, CEO of IonQ. 'The ability to model catalytic reactions with speed and accuracy isn't just a scientific achievement, it's a preview of how hybrid computing with quantum acceleration will provide revolutionary capabilities to the industry.' 'This collaboration marks an important step towards accurately modeling activation barriers for catalyzed reactions relevant to route optimizing in drug development. We look forward to further advancements in the area,' said Anders Broo, Executive Director, Pharmaceutical Science, R&D, AstraZeneca. 'Future quantum computers are not going to replace traditional compute, but instead accelerate specific, computationally intensive processing steps as part of HPC processing pipelines,' said Eric Kessler, GM of Amazon Braket at AWS. 'By combining quantum computers on Amazon Braket with scalable GPU resources on AWS, we're supporting AstraZeneca to envision how future quantum computers will be used to accelerate research in computational chemistry.' 'Bringing together state-of-the-art quantum and GPU computing in hybrid workflows is the path to realizing quantum's potential,' said Tim Costa, Senior Director of Quantum and CUDA-X at NVIDIA. 'This work represents a meaningful step towards applying quantum accelerated supercomputing to important use cases.' IonQ and its partners demonstrated a large-scale, end-to-end simulation of a Suzuki-Miyaura reaction, which is the most complex chemical simulation run on IonQ hardware to date. The hybrid quantum-classical workflow – orchestrated via CUDA-Q on Amazon Braket, accelerated with NVIDIA H200 GPUs through AWS ParallelCluster – delivered more than a 20x speedup in time-to-solution compared to prior benchmarks. This advancement highlights the scalability of IonQ's quantum systems and their practical potential in pharmaceutical R&D. These results show how hybrid quantum computing can overcome computational limits in high-accuracy molecular modeling and enables the analysis of more complex chemical systems. It builds on recent IonQ demonstrations of practical applications where hybrid quantum-classical approaches outperformed purely classical methods. For more information on this research, please visit the IonQ booth #A25 at the ISC High Performance conference in Hamburg, Germany on June 10-13, 2025 or read the full research paper at our technical blog post. About IonQ IonQ, Inc. is a leading commercial quantum computing and networking company, delivering high-performance systems aimed at solving the world's largest and most complex commercial and research use cases. IonQ's current generation quantum computers, IonQ Forte and IonQ Forte Enterprise, are the latest in a line of cutting-edge systems, boasting 36 algorithmic qubits. The company's innovative technology and rapid growth were recognized in Newsweek's 2025 Excellence Index 1000, Forbes' 2025 Most Successful Mid-Cap Companies list, and Built In's 2025 100 Best Midsize Places to Work in Washington DC and Seattle, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words 'accessible,' 'aimed,' 'available,' 'can,' 'cutting-edge,' 'delivering,' 'enables,' 'growth,' 'innovative,' 'impactful,' 'latest,' 'leader,' 'leading,' 'making,' 'potential,' 'provide,' 'solving,' 'toward,' 'will,' and other similar expressions are intended to identify forward-looking statements. These statements include those related to the IonQ's quantum computing capabilities and plans; IonQ's technology driving commercial quantum advantage or delivering scalable, fault-tolerant quantum computing in the future; the relevance and utility of quantum algorithms and applications run on IonQ's quantum computers; the necessity, effectiveness, and future impacts of IonQ's offerings available today; and the scalability, fidelity, efficiency, viability, accessibility, effectiveness, importance, reliability, performance, speed, impact, practicality, feasibility, significance, and commercial-readiness of IonQ's offerings. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: IonQ's ability to implement its technical roadmap; changes in the competitive industries in which IonQ operates, including development of competing technologies; IonQ's ability to deliver, and customers' ability to generate, value from IonQ's offerings; and IonQ's ability to deliver higher speed and fidelity gates with fewer errors, enhance information transfer and network accuracy, or reduce noise and errors. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company's filings, including but not limited to those described in the 'Risk Factors' section of IonQ's most recent periodic financial report (10-Q or 10-K) filed by IonQ with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations. IonQ may or may not choose to practice or otherwise use the inventions described in the issued patents in the future. View source version on CONTACT: IonQ Media contact: Jane Mazur [email protected] Investor Contact: [email protected] KEYWORD: GERMANY EUROPE UNITED STATES NORTH AMERICA MARYLAND INDUSTRY KEYWORD: SOFTWARE RESEARCH NETWORKS INTERNET HARDWARE PHARMACEUTICAL DATA MANAGEMENT TECHNOLOGY SEMICONDUCTOR SCIENCE BIOTECHNOLOGY HEALTH OTHER SCIENCE SOURCE: IonQ Copyright Business Wire 2025. PUB: 06/09/2025 07:05 AM/DISC: 06/09/2025 07:05 AM
